HTT and juvenile Huntington disease: Administration of AAV5-miHTT suppressed mutant HTT mRNA, resulting in almost complete prevention of mutant HTT aggregate formation and suppression of DARPP-32-associated neuronal dysfunction in a rat model for Huntington’s disease [226].